BBH — VanEck Biotech ETF
Data updated: 2026-08-26
BBH — VanEck Biotech ETF. United States Mid Cap Blend / Core Health Care Equity · $395.55M AUM. Holdings, fees, performance and SEC filings.
BBH Fund Overview
BBH — VanEck Biotech ETF is a US ETF managed by VanEck ETF Trust, categorised as United States Mid Cap Blend / Core Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: VanEck ETF Trust
- Category: United States Mid Cap Blend / Core Health Care Equity
- Assets under management: $395.55M
- 1-year return: 33.2%
- Ticker: BBH
- SEC CIK: 0001137360
- SEC series ID: S000034406
- Share class ID: C000105864
BBH Holdings
Top 10 holdings of VanEck Biotech ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Amgen Inc | 15.25% |
| Gilead Sciences Inc | 12.79% |
| Vertex Pharmaceuticals Inc | 9.10% |
| Regeneron Pharmaceuticals Inc | 6.21% |
| Revolution Medicines Inc | 5.27% |
| Argenx SE | 4.97% |
| Natera Inc | 4.92% |
| IQVIA Holdings Inc | 4.31% |
| Alnylam Pharmaceuticals Inc | 3.83% |
| Biogen Inc | 3.63% |
BBH Portfolio Allocation
Asset-class allocation of VanEck Biotech ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 100.0% |
| Cash & Equivalents | 0.1% |
BBH Performance
Total returns for BBH (as of 2026-09-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 7.4% |
| 1 year | 33.2% |
| 3 years (annualised) | 9.8% |
| 5 years (annualised) | 0.6% |
BBH Risk Information
Risk metrics for BBH, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 16.6%
BBH Costs and Fees
BBH costs about $35 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.35%
- Gross expense ratio: 0.35%
- Portfolio turnover: 19%
- Brokerage commissions: 1.30 bps of average net assets (SEC N-CEN)
BBH Cashflows
Over the 12 months to 2026-06, VanEck Biotech ETF had net outflows of $36.22M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-06 | $19.13K |
| 2026-05 | −$3.66M |
| 2026-04 | −$1.90M |
| 2026-03 | $364.51K |
| 2026-02 | −$1.95M |
| 2026-01 | $69.04K |
BBH Debt Constituents
No individual debt constituents are reported in VanEck Biotech ETF's latest SEC N-PORT filing.
BBH Prospectus and SEC Filings
Official VanEck Biotech ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2026-01-27
- Prospectus (485BPOS) — filed 2025-01-27
- Prospectus (485BPOS) — filed 2024-01-26
- Portfolio holdings (N-PORT) — filed 2026-08-26
- Portfolio holdings (N-PORT) — filed 2026-05-28
- Portfolio holdings (N-PORT) — filed 2026-02-27
- Annual census (N-CEN) — filed 2025-12-09
- Annual census (N-CEN) — filed 2024-12-12
Related Funds
Other United States Mid Cap Blend / Core Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.